Qiao, H., Ren, W
This mechanism is therapeutically beneficial for glycemic control but can decrease bioavailability of compounds requiring rapid gastric transit, particularly time-sensitive medications like oral contraceptives
It is not intended for human or animal consumption, therapeutic use, clinical application, or diagnostic purposes
Whether too much or too little, inform your provider
This case study , published in 2023, describes three female patients taking semaglutide who visited their healthcare clinic due to severe mouth dryness, as well as minimal frothy saliva. After underlying medical problems were excluded (such as low water intake or a condition called Sjogrens disease) as the cause, the females were diagnosed with hyposalivation (dry mouth)
These minor side effects are most common when patients start taking Wegovy and other semaglutides or GLP-1 medications